中文摘要：

目的：系统评价参芪降糖颗粒治疗糖尿病肾病Ⅲ期的疗效及安全性。方法：计算机检索PubMed、Medline、EMbase、Ovid、CNKI、Wanfang data、VIP、CBM等中外文数据库，查找关于参芪降糖颗粒治疗糖尿病Ⅲ期的随机对照试验。然后根据预设的纳入排除标准筛查文献，对筛选出的文献进行质量评价和提取资料，最后对提取的数据使用RevMan 5.2软件进行Meta分析。结果：共纳入10个研究，722例患者，其中试验组368例，对照组354例。与单纯常规治疗组相比，在常规治疗基础上加用参芪降糖颗粒在改善尿微量白蛋白排泄率、血肌酐及有效率等方面更具优势（P〈0.05）。结论：基于现有临床证据，参芪降糖颗粒联合常规治疗对糖尿病肾病Ⅲ期有一定的疗效，安全性较好，但由于纳入研究的质量不高，此结论尚需更多大样本、多中心、高质量的临床随机对照试验加以证实。

英文摘要：

Objective：To systematicaly review the effectiveness and safety of Shenqi Sugar Declining Granules on treating Ⅲ stage of diabetic nephropathy. Methods：By covering database such as PubMed、Medline、EMbase、Ovid、CNKI、Wanfang data、CBM,we searched randomized controled trials about Shenqi Sugar Declining Granules on treating Ⅲ stage of diabetic nephropathy. After selecting studies based on inclusion and exclusion criteria,we estimated the qualities of studies and extracting data. Finaly,a meta-analysis was conducted using RevMan 5.2 to make a ful systematic review. Results：A total of 10 studies involving 722 participants were included. Compared to the conventional treatment alone,Shenqi Sugar Declining Granules plus conventional treatment showed better effect on improving UAER、SCr and effectiveness（P〈0.05）.Conclusion：Based on the existing evidence,Shenqi Sugar Declining Granules has a safe and curative effect on treating Ⅲ stage of diabetic nephropathy. However,as most of the include studies were regarded as low qualities,large sample、multi-center and wel-designed researches need to be applied.